Strategic Acquisition LSO acquired J-Pac Medical in 2023 and continues to expand by acquiring strategic manufacturing assets in 2025, indicating a growth trajectory and increased capacity for end-to-end medical device manufacturing, packaging, and sterilization services that can support customers seeking scale.

End-to-End Competence The company emphasizes in-house end-to-end portfolio processes with deep regulatory knowledge, offering streamlined go-to-market launches and standardized supply chains, which can appeal to firms seeking risk mitigation and faster time-to-market.

Leadership Momentum New CEO Doug Constable appointed in 2025 signals strategic direction and potential to accelerate sales efforts, partnerships, and geographic or service expansions that can benefit clients needing robust leadership and vision.

Medical Device Focus Specialization in assembly, packaging, sterilization, and diagnostics wet reagent packaging positions LSO as a turnkey CMO for medical devices and diagnostics seeking compliant manufacturing and cost-effective outsourcing.

Growth Signals Revenue range and mid-size employee footprint suggest a scalable partner capable of handling growing MID-market programs; cross-sell opportunities exist across adjacent services and asset-based capabilities, including strategic asset deployment and enhanced manufacturing flexibility.